Article History
Accepted: 18 May 2022
First Online: 1 July 2022
Competing interests
: D.A.F. has received grants from Astex Therapeutics, Bayer, Boehringer Ingelheim and MSD; personal fees from Aldeyra, Inventiva, Paredox and Roche; and non-financial support (involving the provision of study drugs) from Bergen Bio, BMS, Clovis Oncology, Eli Lilly, Pierre Fabre and Roche. The other authors declare no competing interests.